Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites and methods of use thereof
Modified forms of hemagglutinin (HA) protein including those with modified immunodominant regions and with modified maturation cleavage sites, and virus and virus-like particles containing them are disclosed.
1. A modified hemagglutinin (HA) protein of influenza virus comprising a globular head domain and a stem domain, wherein at least one immunodominant region of the globular head domain of said HA protein contains an influenza stem epitope, wherein said influenza stem epitope comprises one or more stem peptides of the same HA and is recognized by a broadly neutralizing antibody (bnAb) against influenza viruses.
2. The modified HA protein of claim 1 , wherein the at least one immunodominant region of the globular head domain contains said influenza stem epitope by insertion into said domain, or contains said stem epitope by replacing said domain with said influenza stem epitope.
3. The modified HA protein of claim 1 , wherein the at least one immunodominant region of the globular head domain is at least two, at least three, at least four, or at least five immunodominant regions.
4. The modified HA protein of claim 3 , wherein the one or more stem epitopes contained in the at least two, at least three, at least four, or at least five immunodominant regions of the globular head domain are distinct.
5. The modified HA protein of claim 3 , wherein the one or more stem epitopes contained in the at least two, at least three, at least four, or at least five immunodominant regions of the globular head domain are identical.
6. The modified HA protein of claim 1 , wherein said HA protein is contained in a live or attenuated virus or in a virus-like particle (VLP).
7. A polynucleotide encoding the modified HA protein of claim 1 .
8. A recombinant influenza virus, wherein the recombinant virus comprises the polynucleotide of claim 7 , such that the modified HA protein is expressed on the surface of the virus.
9. A recombinant host cell comprising the polynucleotide of claim 7 .
10. An immunogenic composition comprising the modified HA protein of claim 1 .
11. The immunogenic composition of claim 10 , wherein the composition comprises a live or attenuated virus or VLP.
12. An immunogenic composition comprising the polynucleotide of claim 7 .
13. A method to generate antibodies against influenza viruses, which method comprises administering to a subject the immunogenic composition of claim 10 .
14. A method to generate antibodies against influenza viruses, which method comprises administering to a subject the immunogenic composition of claim 12 .